EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

VSee Health, Inc. (VSEE) fair value: what the stock is really worth

We calculate from audited financials what VSee Health, Inc. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jul 31, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US92919Y1029

VH VSee Health, Inc. logo Thin data Jul 31, 2026

VSee Health, Inc.

VSEE · US

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value $6.25 · Strongly undervalued (+197.1%)
!Quality 22/100
!Expensive Growth (revenue 5y +16.5 %/yr)
!Loss-making · -92.4% net margin (TTM)
!negative free cash flow
!Trails peers (0/6)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Watch VSee Health, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$24.24 $0.3200 Fair Value $6.25 Dec 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.

How to read this chart

57‑month range $0.3200 – $24.24 · fair‑value band $5.08 – $8.01 · the $2.10 price screens below the $6.25 fair value. Dashed = 300-day average. As of Jul 31, 2026.

Follow VSee Health in your weekly email

Every Wednesday you see whether VSee Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

VSee Health, Inc. provides telehealth care solutions in the United States. The company offers iDoc Telehealth solutions that treat and coordinate care for acutely ill patients in the neurointensive care, cardiac intensive care, and intensive care units for stroke, spinal cord, brain trauma, and other neurological conditions.

Show more

VSee Health, Inc. provides telehealth care solutions in the United States. The company offers iDoc Telehealth solutions that treat and coordinate care for acutely ill patients in the neurointensive care, cardiac intensive care, and intensive care units for stroke, spinal cord, brain trauma, and other neurological conditions. It also provides telehealth software building blocks, such as patient engagement, clinician staffing, remote physical exam and remote patient monitoring, and AI for telesitter and telenursing solutions; data connectors; and workflow templates. The company distributes its products through third-party resellers and affiliated hospitals, as well as sales executives. The company is headquartered in Newton, Massachusetts.

Stock analysis

VSee Health, Inc. (VSEE) currently trades at $2.10, while our model-based Fair Value estimate is $6.25, implying the stock looks roughly 66.3% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $5.08 (bear) to $8.01 (bull), the price of $2.10 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

VSee Health, Inc. reported revenue of $14.6M in FY2025 versus $7.3M in FY2021, a compound +18.8%/yr. Reported net income was −$14.7M in FY2025.

Key figures

Market cap $5.9M · P/S ratio 0.41 · EPS (TTM) $−0.5400 · Net margin −101% · Return on equity −946% · Return on assets (EBIT) −72.6% · Operating margin −94.1% · Revenue (TTM) $14.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 91% below its 52-week high and 557% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 197%, VSEE screens cheaper than that median.

Fair Value models

Bear $5.08 Fair Value $6.25 Bull $8.01
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0600 $0.0800 $0.1100 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.0600 $0.0800 $0.1100 52

Open the full fair value analysis →

Notify me when VSEE reaches fair value

Put VSEE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 22/100

Of which business quality 25 · Market factors (momentum, volatility) 44

Profitability 21
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 45
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 54
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+40.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.5%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26.3% (2022) → −65.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch VSEE, get fair value alerts →

Compare VSee Health, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 129 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Profitability
Return on assets −34.9% · Bottom 25%
Net margin (TTM) −92.4% · Bottom 25%
Operating margin (TTM) −94.1% · Bottom 25%
Growth and dividend
Revenue growth −4.9% · Bottom 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $278.57 $306.43 +10%
Pro Medicus Limited PME A$161.00 A$84.62 −47%
BrightSpring Health Services, Inc BTSG $56.54 $25.86 −54%
Hinge Health, Inc HNGE $95.57 $51.25 −46%
HealthEquity, Inc HQY $88.44 $97.28 +10%
Waystar Holding WAY $24.70 $27.17 +10%
Doximity, Inc DOCS $26.35 $31.41 +19%
XtalPi Holdings 2228 HK$7.75 HK$1.50 −81%
Inventurus Knowledge Solutions Limited IKS ₹1,779 ₹1,883 +6%
Privia Health Group PRVA $19.62 $5.02 −74%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

VSee Health, Inc. · Fair Value
$6.25 +66%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "VSee Health, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/VSEE

Frequently asked questions

Is VSee Health, Inc. (VSEE) overvalued or undervalued?
As of Jul 31, 2026, our model estimates a fair value of $6.25 versus a price of $2.10, about +197% upside (undervalued).
What is the fair value of VSEE?
Our model-based fair value for VSee Health, Inc. is $6.25 (as of Jul 31, 2026), built from audited fundamentals. The current price: $2.10.
What is the quality score of VSEE?
VSee Health, Inc. has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for VSee Health, Inc. (VSEE)?
Our model-based price target is the fair value of $6.25 (as of Jul 31, 2026) from 1 valuation models. Cautious scenario $5.08, optimistic scenario $8.01. It is a calculation from audited fundamentals, not an analyst target.
What is the VSee Health, Inc. stock forecast for 2026?
Our models put fair value at $6.25, about +197% upside versus a price of $2.10 (undervalued). Cautious scenario $5.08, optimistic scenario $8.01. The calculation is refreshed regularly with new filings.
What is the revenue of VSee Health, Inc. (VSEE)?
VSee Health, Inc. reported trailing-twelve-month revenue of about $14.5M (latest available figure, as of Jul 31, 2026).
What is the intrinsic value of VSee Health, Inc. (VSEE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For VSee Health, Inc. it is $6.25 per share (as of Jul 31, 2026), against a price of $2.10. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is VSee Health, Inc. stock overvalued or undervalued in 2026?
As of Jul 31, 2026, VSEE trades below its calculated fair value: price $2.10, fair value $6.25, a gap of about +197% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VSEE?
No. The price is what the market pays today ($2.10); the fair value is what the company's own numbers justify ($6.25). For VSee Health, Inc. the two are $4.14 per share apart. That gap is exactly why we show both numbers side by side.
How much is VSee Health, Inc. worth?
The market values VSee Health, Inc. at about $5.9M (market capitalisation, as of Jul 31, 2026). Per share that is $2.10; our models calculate a fair value of $6.25 per share.
What do the bullish and bearish scenarios say about VSEE?
Our models span a range for VSee Health, Inc.: cautious scenario $5.08, base $6.25, optimistic $8.01 per share (as of Jul 31, 2026, price $2.10). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is VSEE from its 52-week high?
VSee Health, Inc. trades at $2.10, about 91% below its 52-week high of $24.24 and 557% above the low of $0.3200 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of $6.25 is for.
Which stocks are comparable to VSee Health, Inc.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is VSee Health, Inc. stock attractive at the current price?
The data as of Jul 31, 2026: price $2.10, calculated fair value $6.25 (+197%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VSEE calculated?
We run VSee Health, Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $6.25, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. VSee Health, Inc. currently trades 66 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of VSee Health, Inc. (VSEE)?
The closing price on Oct 1, 2026 was $2.10. Our model-based fair value is $6.25, about +197% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with VSee Health, Inc. right now?
The large discount to fair value meets weak quality (22/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($5.08). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of VSee Health, Inc.

How large is the market capitalisation of VSee Health, Inc. (VSEE)?
The market capitalisation of VSee Health, Inc. is $5.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of VSee Health, Inc. (VSEE)?
The price-to-sales ratio of VSee Health, Inc. is 0.41 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of VSee Health, Inc. (VSEE)?
Earnings per share at VSee Health, Inc. are $−0.5400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of VSee Health, Inc. (VSEE)?
The net margin of VSee Health, Inc. is −101% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of VSee Health, Inc. (VSEE)?
The return on equity (ROE) of VSee Health, Inc. is −946% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of VSee Health, Inc. (VSEE)?
On an EBIT basis the return on assets of VSee Health, Inc. is −72.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of VSee Health, Inc. (VSEE)?
The operating margin of VSee Health, Inc. is −94.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at VSee Health, Inc. (VSEE)?
Revenue at VSee Health, Inc. is growing −4.9% versus a year earlier (3y avg +31.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does VSee Health, Inc. (VSEE) generate?
The free cash flow of VSee Health, Inc. is −$3.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does VSee Health, Inc. (VSEE) hold?
VSee Health, Inc. holds more cash than debt, $2.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch VSee Health, Inc. in the live analysis

One click puts VSee Health, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.